Voxel in 2026: a Kraków operator of medical-imaging centres and radiopharmaceuticals, an mWIG40 issuer with a two-member management board

Voxel in 2026: a Kraków operator of medical-imaging centres, an mWIG40 issuer with a two-member management board, NFZ contracts as the revenue backbone

Voxel S.A. – headquartered at ul. Wielicka 265 in Kraków (postcode 30-663), registered in the KRS under number 0000238176 – is a Kraków-based operator of a medical-imaging centre network. Under the Voxel-Diagnostic brand, the company runs several dozen clinics across Poland:

• Magnetic resonance imaging (MRI) – the most technologically advanced imaging modality and Voxel's dominant revenue segment.
• Computed tomography (CT) – the second main segment.
• X-ray (conventional and digital), ultrasound, mammography – supporting examinations.
• Radiopharmaceuticals – vertically integrated production of isotopes for PET-CT scans.

The company has operated in its current legal form (a joint-stock company under KRS 0000238176) since 2 August 2005 and has been listed on the Warsaw Stock Exchange since November 2011 – the first major Polish ticker in the medical-imaging sector. Its corporate signature: Voxel's management board has just two members (CEO plus vice-president), making it one of the smallest boards in the mWIG40. The supervisory board has five members.

According to the company's 2025 financial statements, group revenue reached PLN 583.8 million, up 15% from PLN 507.8 million a year earlier, with net profit of PLN 98.5 million (versus PLN 96.5 million in 2024, up 2%).

Voxel

KRAKÓW · KRS 0000238176 · SPÓŁKA AKCYJNA

Revenue

583.8 M PLN

Wielicka 265, Kraków: the city's healthcare cluster

The address ul. Wielicka 265, 30-663 Kraków, places Voxel's registered office in the south-eastern part of Kraków, on Wielicka street (the main route out of the city toward Wieliczka and Tarnów) – adjacent to the University Hospital and other medical complexes. It is a strategically important location for a diagnostics company: proximity to large hospitals means proximity to patients referred by specialists for imaging examinations.

The company has a registered electronic-delivery address (ADE: PL-23931-31079-GCEDG-25) and a website at voxel.pl. Under Polish PKD codes, its principal activities include 86 (human health activities) – notably 8622 (specialist medical practice, which covers medical imaging) – and 21 (manufacture of basic pharmaceutical products, for the radiopharmaceutical segment).

Voxel operates two complementary business models:

• B2C/B2B medical imaging – patients referred for examinations by specialist physicians. Payers: the NFZ (public funding), private insurers (Medicover, LUX MED, Compensa), or the patient directly.
• Radiopharmaceuticals for PET-CT – production of isotopes (mainly ⁹⁹ᵐTc-octreotide and FDG) sold to other diagnostic centres. Voxel owns its PET-CT machines and its radiopharmaceutical production is vertically integrated.

The Polish medical-imaging market: growing privatisation of segments

The Polish medical-imaging market is narrowly represented on the Warsaw exchange – Voxel is practically the only large, purely diagnostics-focused mWIG40 player. Its competitors sit off-exchange:

• LUX MED – a private medical group (controlled by Britain's Bupa) with its own diagnostic clinics.
• Medicover – an international medical group with a Polish presence and its own clinics.
• Affidea – a private network of medical-imaging centres, controlled by a private-equity fund.
• Public diagnostics – NFZ-funded hospitals and public institutions, which perform most MRI/CT examinations in Poland.

Three structural features of the Voxel model explain its mWIG40 positioning:

• Structural demand for diagnostics – the ageing of Polish society, the development of precision medicine, and the rising incidence of lifestyle diseases (cancer, neurological conditions) generate structurally growing demand for imaging. This gives Voxel a long-term revenue base.
• Exposure to NFZ tariffs – most of Voxel's revenue comes from contracts with the National Health Fund (NFZ). Any change in MRI/CT tariffs directly affects group profitability, making the company sensitive to regulation – even in a year of rising examination volumes, low tariffs can mean thin margins.
• A capital-intensive model – a single MRI machine costs PLN 5–10 million, a PET-CT machine PLN 10–20 million. Voxel must regularly modernise its equipment fleet, which requires significant capex, limits the room for generous dividends, and demands a long-term investment horizon.

Implications for the investment profile: stable demand, moderate dividend, regulatory exposure

“Voxel is a classic case of a Polish health-tech-services company - an operator of private diagnostic centres in a sector that grows structurally with the ageing of the Polish population. A minority investor here commits to exposure to the rising privatisation of the Polish healthcare sector, while bearing regulatory risk from NFZ tariffs and the capital intensity of equipment modernisation.”

Three expected consequences for the company's 2026 investment profile:

• A moderate dividend policy – Voxel has historically paid dividends of PLN 0.80–2.50 per share (a 2–5% yield), positioning itself as a regular but not particularly generous payer. The policy remains a function of balancing investment in new equipment against shareholder distributions.
• Structural diagnostic demand in 2026 – Poland continues the gradual privatisation of its healthcare sector, and population ageing (median age around 42) keeps driving demand for imaging. Voxel is a natural beneficiary.
• The key: NFZ decisions in 2026 – any change in NFZ tariffs for MRI/CT examinations in 2026 (expected in the second half of the year) will be a meaningful event for the company's valuation. Higher tariffs mean margin improvement; cuts mean pressure on profitability.

For the Małopolskie voivodeship, Voxel is a smaller but specialised mWIG40 issuer – Kraków, the regional capital, hosts a clearly concentrated health-tech cluster (Voxel in diagnostics, Mercator Medical in disposables, Mabion and Ryvu in biotech), making the region one of Poland's leading health-tech hubs.

What you'll find in the Voxel profile

The Voxel S.A. profile in our database gives the full picture of the company: the composition of the two-member management board (CEO plus vice-president – one of the smallest in the Polish mWIG40), the five-member supervisory board, the KRS registration history from 2 August 2005, the registered address at ul. Wielicka 265 in Kraków, e-delivery status (ADE PL-23931-31079-GCEDG-25), the voxel.pl website, and the assigned PKD codes classifying the business as health activities. The profile is also available in English – relevant for international healthcare-focused funds, since Voxel is the only large Polish mWIG40 issuer in the medical-imaging segment.

Data: Polish KRS Court Register (KRS 0000238176); Voxel S.A. - annual reports 2023–2025; financial statements filed with KRS; PKD classification 86/21 (health activities and pharmaceutical production); company history - founded 2005, S.A. 2005, WSE IPO November 2011; editorial estimates for the position in the Polish medical-imaging sector, as of 2026-07-27.